Disability Improvement Is Associated with Less Brain Atrophy Development in Multiple Sclerosis

References

1. 1.↵
   2. Frohman EM,
   3. Racke MK,
   4. Raine CS

   . Multiple sclerosis: the plaque and its pathogenesis. N Engl J Med 2006;354:942–55 doi:10.1056/NEJMra052130 pmid:16510748

   CrossRefPubMedWeb of Science
2. 2.↵
   2. Calabrese M,
   3. Reynolds R,
   4. Magliozzi R, et al

   . Regional distribution and evolution of gray matter damage in different populations of multiple sclerosis patients. PLoS One 2015;10:e0135428 doi:10.1371/journal.pone.0135428 pmid:26267665

   CrossRefPubMed
3. 3.↵
   2. Fisher E,
   3. Lee JC,
   4. Nakamura K, et al

   . Gray matter atrophy in multiple sclerosis: a longitudinal study. Ann Neurol 2008;64:255–65 doi:10.1002/ana.21436 pmid:18661561

   CrossRefPubMedWeb of Science
4. 4.↵
   2. De Stefano N,
   3. Giorgio A,
   4. Battaglini M, et al

   . Assessing brain atrophy rates in a large population of untreated multiple sclerosis subtypes. Neurology 2010;74:1868–76 doi:10.1212/WNL.0b013e3181e24136 pmid:20530323

   Abstract/FREE Full Text
5. 5.↵
   2. Zivadinov R,
   3. Sepcic J,
   4. Nasuelli D, et al

   . A longitudinal study of brain atrophy and cognitive disturbances in the early phase of relapsing-remitting multiple sclerosis. J Neurol Neurosurg Psychiatry 2001;70:773–80 doi:10.1136/jnnp.70.6.773 pmid:11385012

   Abstract/FREE Full Text
6. 6.↵
   2. Miller DH,
   3. Barkhof F,
   4. Frank JA, et al

   . Measurement of atrophy in multiple sclerosis: pathological basis, methodological aspects and clinical relevance. Brain 2002;125:1676–95 doi:10.1093/brain/awf177 pmid:12135961

   CrossRefPubMedWeb of Science
7. 7.↵
   2. Uher T,
   3. Horakova D,
   4. Kalincik T, et al

   . Early magnetic resonance imaging predictors of clinical progression after 48 months in clinically isolated syndrome patients treated with intramuscular interferon beta-1a. Eur J Neurol 2015;22:1113–23 doi:10.1111/ene.12716 pmid:25904020

   CrossRefPubMed
8. 8.↵
   2. Lukas C,
   3. Minneboo A,
   4. de Groot V, et al

   . Early central atrophy rate predicts 5-year clinical outcome in multiple sclerosis. J Neurol Neurosurg Psychiatry 2010;81:1351–56 doi:10.1136/jnnp.2009.199968 pmid:20826873

   Abstract/FREE Full Text
9. 9.↵
   2. Minneboo A,
   3. Jasperse B,
   4. Barkhof F, et al

   . Predicting short-term disability progression in early multiple sclerosis: added value of MRI parameters. J Neurol Neurosurg Psychiatry 2008;79:917–23 doi:10.1136/jnnp.2007.124123 pmid:18077480

   Abstract/FREE Full Text
10. 10.↵
    2. Sanai SA,
    3. Saini V,
    4. Benedict RH, et al

    . Aging and multiple sclerosis. Mult Scler 2016;22:717–25 doi:10.1177/1352458516634871 pmid:26895718

    CrossRefPubMed
11. 11.↵
    2. Sastre-Garriga J,
    3. Pareto D,
    4. Rovira A

    . Brain atrophy in multiple sclerosis: clinical relevance and technical aspects. Neuroimaging Clin N Am 2017;27:289–300 doi:10.1016/j.nic.2017.01.002 pmid:28391787

    CrossRefPubMed
12. 12.↵
    2. Zivadinov R,
    3. Uher T,
    4. Hagemeier J, et al

    . A serial 10-year follow-up study of brain atrophy and disability progression in RRMS patients. Mult Scler 2016;22:1709–18 doi:10.1177/1352458516629769 pmid:26883943

    CrossRefPubMed
13. 13.↵
    2. Coles AJ,
    3. Twyman CL,
    4. Arnold DL, et al

    . Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet 2012;380:1829–39 doi:10.1016/S0140-6736(12)61768-1 pmid:23122650

    CrossRefPubMedWeb of Science
14. 14.↵
    2. Calabresi PA,
    3. Radue EW,
    4. Goodin D, et al

    . Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, Phase 3 trial. Lancet Neurol 2014;13:545–56 doi:10.1016/S1474-4422(14)70049-3 pmid:24685276

    CrossRefPubMedWeb of Science
15. 15.↵
    2. Montalban X,
    3. Hauser SL,
    4. Kappos L, et al

    ; ORATORIO Clinical Investigators. Ocrelizumab versus placebo in primary progressive multiple sclerosis. N Engl J Med 2017;376:209–20 doi:10.1056/NEJMoa1606468 pmid:28002688

    CrossRefPubMed
16. 16.↵
    2. Hauser SL,
    3. Bar-Or A,
    4. Comi G, et al

    ; OPERA I and OPERA II Clinical Investigators. Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. N Engl J Med 2017;376:221–34 doi:10.1056/NEJMoa1601277 pmid:28002679

    CrossRefPubMed
17. 17.↵
    2. O'Connor P,
    3. Wolinsky JS,
    4. Confavreux C, et al

    ; TEMSO Trial Group. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med 2011;365:1293–1303 doi:10.1056/NEJMoa1014656 pmid:21991951

    CrossRefPubMedWeb of Science
18. 18.↵
    2. Borges IT,
    3. Shea CD,
    4. Ohayon J, et al

    . The effect of daclizumab on brain atrophy in relapsing-remitting multiple sclerosis. Mult Scler Relat Disord 2013;2:133–40 doi:10.1016/j.msard.2012.10.002 pmid:23580931

    CrossRefPubMed
19. 19.↵
    2. Giovannoni G,
    3. Comi G,
    4. Cook S, et al

    ; CLARITY Study Group. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N Engl J Med 2010;362:416–26 doi:10.1056/NEJMoa0902533 pmid:20089960

    CrossRefPubMedWeb of Science
20. 20.↵
    2. Chen JT,
    3. Collins DL,
    4. Atkins HL

    ; Canadian MS BMT Study Group. Brain atrophy after immunoablation and stem cell transplantation in multiple sclerosis. Neurology 2006;66:1935–37 doi:10.1212/01.wnl.0000219816.44094.f8 pmid:16801665

    Abstract/FREE Full Text
21. 21.↵
    2. Sicotte NL,
    3. Giesser BS,
    4. Tandon V, et al

    . Testosterone treatment in multiple sclerosis: a pilot study. Arch Neurol 2007;64:683–88 doi:10.1001/archneur.64.5.683 pmid:27752863

    CrossRefPubMedWeb of Science
22. 22.↵
    2. Uher T,
    3. Horakova D,
    4. Bergsland N, et al

    . MRI correlates of disability progression in patients with CIS over 48 months. Neuroimage Clin 2014;6:312–19 doi:10.1016/j.nicl.2014.09.015 pmid:25379444

    CrossRefPubMed
23. 23.↵
    2. Polman CH,
    3. Reingold SC,
    4. Banwell B, et al

    . Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 2011;69:292–302 doi:10.1002/ana.22366 pmid:21387374

    CrossRefPubMedWeb of Science
24. 24.↵
    2. Gelineau-Morel R,
    3. Tomassini V,
    4. Jenkinson M, et al

    . The effect of hypointense white matter lesions on automated gray matter segmentation in multiple sclerosis. Hum Brain Mapp 2012;33:2802–14 doi:10.1002/hbm.21402 pmid:21976406

    CrossRefPubMed
25. 25.↵
    2. Smith SM,
    3. Zhang Y,
    4. Jenkinson M, et al

    . Accurate, robust, and automated longitudinal and cross-sectional brain change analysis. Neuroimage 2002;17:479–89 doi:10.1006/nimg.2002.1040 pmid:12482100

    CrossRefPubMedWeb of Science
26. 26.↵
    2. Dwyer MG,
    3. Silva D,
    4. Bergsland N, et al

    . Neurological software tool for reliable atrophy measurement (NeuroSTREAM) of the lateral ventricles on clinical-quality T2-FLAIR MRI scans in multiple sclerosis. Neuroimage Clin 2017;15:769–79 doi:10.1016/j.nicl.2017.06.022 pmid:28706852

    CrossRefPubMed
27. 27.↵
    2. Zivadinov R,
    3. Rudick RA,
    4. De Masi R, et al

    . Effects of IV methylprednisolone on brain atrophy in relapsing-remitting MS. Neurology 2001;57:1239–47 doi:10.1212/WNL.57.7.1239 pmid:11591843

    Abstract/FREE Full Text
28. 28.↵
    2. Coles AJ,
    3. Cohen JA,
    4. Fox EJ, et al

    ; CARE-MS II and CAMMS03409 Investigators. Alemtuzumab CARE-MS II 5-year follow-up: efficacy and safety findings. Neurology 2017;89:1117–26 doi:10.1212/WNL.0000000000004354 pmid:28835403

    Abstract/FREE Full Text
29. 29.↵
    2. Correale J,
    3. Peirano I,
    4. Romano L

    . Benign multiple sclerosis: a new definition of this entity is needed. Mult Scler 2012;18:210–18 doi:10.1177/1352458511419702 pmid:21865415

    CrossRefPubMed
30. 30.↵
    2. Ghione E,
    3. Bergsland N,
    4. Dwyer MG, et al

    . Brain atrophy is associated with disability progression in patients with MS followed in a clinical routine. AJNR Am J Neuroradiol 2018;39:2237–42 doi:10.3174/ajnr.A5876 pmid:30467212

    Abstract/FREE Full Text
31. 31.↵
    2. Zivadinov R,
    3. Bergsland N,
    4. Korn JR, et al

    ; MS-MRIUS Study Group. Feasibility of brain atrophy measurement in clinical routine without prior standardization of the MRI protocol: results from MS-MRIUS, a longitudinal observational, multicenter real-world outcome study in patients with relapsing-remitting MS. AJNR Am J Neuroradiol 2018;39:289–95 doi:10.3174/ajnr.A5442 pmid:29170269

    Abstract/FREE Full Text
32. 32.↵
    2. Ghione E,
    3. Bergsland N,
    4. Dwyer MG, et al

    . Aging and brain atrophy in multiple sclerosis. J Neuroimaging 2019;29:527–35 doi:10.1111/jon.12625 pmid:31074192

    CrossRefPubMed
33. 33.↵
    2. Cree BA,
    3. Hollenbach JA,
    4. Bove R, et al

    ; University of California, San Francisco MS-EPIC Team. Silent progression in disease activity-free relapsing multiple sclerosis. Ann Neurol 2019;85:653–66 doi:10.1002/ana.25463 pmid:30851128

    CrossRefPubMed
34. 34.↵
    2. Bakshi R,
    3. Healy BC,
    4. Dupuy SL, et al

    ; SUMMIT consortium. Brain MRI predicts worsening multiple sclerosis disability over 5 years in the SUMMIT Study. J Neuroimaging 2020;30:212–18 doi:10.1111/jon.12688 pmid:31994814

    CrossRefPubMed
35. 35.↵
    2. Gauthier SA,
    3. Berger AM,
    4. Liptak Z, et al

    . Rate of brain atrophy in benign vs early multiple sclerosis. Arch Neurol 2009;66:234–37 doi:10.1001/archneurol.2008.567 pmid:19204160

    CrossRefPubMedWeb of Science
36. 36.↵
    2. Sormani MP,
    3. Arnold DL,
    4. De Stefano N

    . Treatment effect on brain atrophy correlates with treatment effect on disability in multiple sclerosis. Ann Neurol 2014;75:43–49 doi:10.1002/ana.24018 pmid:24006277

    CrossRefPubMed
37. 37.↵
    2. Cohen JA,
    3. Coles AJ,
    4. Arnold DL, et al

    . Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled Phase 3 trial. Lancet 2012;380:1819–28 doi:10.1016/S0140-6736(12)61769-3 pmid:23122652

    CrossRefPubMedWeb of Science
38. 38.↵
    2. Jakimovski D,
    3. Gandhi S,
    4. Paunkoski I, et al

    . Hypertension and heart disease are associated with development of brain atrophy in multiple sclerosis: a 5-year longitudinal study. Eur J Neurol 2019;26:87–88 doi:10.1111/ene.13769 pmid:30103277

    CrossRefPubMed